Financial Data and Key Metrics Changes - Total product revenue for 2022 was $8.2 million, a 20% increase from 2021, with a fourth quarter revenue of $2.1 million, up 16% year-over-year [24] - Gross profit margin improved to 53% for the year compared to 45% in 2021, and 57% for the fourth quarter compared to 55% in the same period last year [24] - Cash used in operations for 2022 was $32.2 million, with an anticipated cash usage for 2023 between $16 million and $19 million [26][15] Business Line Data and Key Metrics Changes - Test volumes increased to 21,423 for the year, a 23% increase, with fourth quarter volume increasing 18% to 5,642 tests [24] - Ova1Plus test volumes contributed significantly to revenue growth, with the average unit price decreasing to $372 for the year [24][29] Market Data and Key Metrics Changes - The company is actively pursuing payer adoption and fair pricing for the OvaSuite test portfolio, achieving important milestones in 2022 [12] - OvaWatch received coverage from a leading global payer shortly after its launch, indicating positive market reception [12] Company Strategy and Development Direction - The company is focused on growth, innovation, and operational excellence, with a commitment to transparency and effective resource utilization [5] - Plans for 2023 include engaging in high-impact media and refining sales strategies to enhance provider adoption [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for OvaWatch and the overall market for ovarian cancer diagnostic tools, emphasizing the critical need for better diagnostics [27] - The company is navigating challenging market conditions while maintaining a focus on revenue growth and operational efficiency [15][49] Other Important Information - The company reduced its workforce by nearly 30%, resulting in significant payroll savings for 2023 [14] - A $12.5 million equity placement was established to enhance liquidity [15] Q&A Session Summary Question: What is the outlook for OvaWatch's average selling price (ASP) following national payer agreements? - Management indicated that establishing payer relationships takes time, but they are optimistic about aligning OvaWatch's ASP with Ova1Plus by the end of the year [29] Question: How are discussions progressing with potential partners for OvaWatch? - Management noted that reimbursement is a key factor for potential partners, and they are actively engaging with interested parties [31][32] Question: What needs to happen from a development and regulatory perspective before launching the endometriosis test? - The availability of high-quality samples for validation remains a challenge, and management is exploring various regulatory paths for the test [36] Question: What feedback is being received on OvaWatch, and is there any cannibalization of Ova1Plus? - Management reported no cannibalization of Ova1Plus and positive feedback from physicians regarding OvaWatch's utility [39] Question: What is the timeline for the serial monitoring assay for OvaWatch? - The company aims to launch the serial monitoring test in the second half of 2023, with ongoing clinical studies supporting its development [43]

Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Robert Beechey - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair & Company Operator Good morning, ladies and gentlemen, and welcome to Aspira Women’s Health Incorporated Third Quarter 2022 Conference ...

Aspira Women's Health, Inc. (NASDAQ:AWH) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Robert Beechey - Chief Financial Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Inc. Second Quarter 2022 Conference Call. My name is Vikram and I will be your coordin ...

Call Start: 08:30 January 1, 0000 9:06 AM ET Aspira Women's Health, Inc. (NASDAQ:AWH) Q1 2022 Earnings Conference Call May 11, 2022, 08:30 ET Company Participants Nicole Sandford - President, Chief Executive Officer and Director Robert Beechey - Chief Financial Officer Michael Newton - Head, Commercial Conference Call Participants Brian Weinstein - William Blair & Company Ross Osborn - Cantor Fitzgerald & Co. Operator Good morning ladies and gentlemen and welcome to Aspira Women's Health Inc. First Quarter ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q4 2021 Results Conference Call March 23, 2022 8:30 AM ET Company Participants Valerie Palmieri - Executive Chair of the Board Nicole Sanford - President and Chief Executive Officer Rob Beechey - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Kumar Raja - Brookline Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health Inc.'s Full Year 2021 and Fourth Quarter 2021 Conference Call. My name is Kyle, and ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Valerie Palmieri - President & Chief Executive Officer Lesley Northrop - Chief Scientific Officer Rob Beechey - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Operator Good morning, ladies and gentlemen, and welcome Aspira Women's Health Incorporated Third Quarter 2021 Conference Call. My name is Paul and I will be your coordinator for the call toda ...